Fig. 1
From: Gains in the current understanding of managing neovascular AMD with brolucizumab
OCT B-scans of a patient switched to brolucizumab to increase the treatment interval duration. A On August 5, 2019, 6 weeks after an aflibercept injection, subretinal fluid was apparent. B On October 16, 2019, 5 weeks after the next aflibercept injection, disease activity was controlled. C On January 27, 2020, 14 weeks after the first brolucizumab injection, the patient showed good disease control. D On May 19, 2020, 15 weeks after the second brolucizumab injection—a longer treatment interval than recommended—disease activity had returned. E On August 28, 2020, 13 weeks after the third brolucizumab injection, there was trace subretinal fluid. F On November 6, 2020, 10 weeks after the fourth brolucizumab injection, there was no disease activity. OCT, optical coherence tomography